Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

New InsiGHTS: A Multicenter, Phase 2, Randomized, Open-label, Active-controlled, Parallel Group Clinical Trial to Investigate the Safety, Tolerability, and Efficacy of Different Dose Levels of Once-weekly Lonapegsomatropin Compared to Daily Somatropin in Prepubertal Individuals With Turner Syndrome

Next Previous
Trial Profile

New InsiGHTS: A Multicenter, Phase 2, Randomized, Open-label, Active-controlled, Parallel Group Clinical Trial to Investigate the Safety, Tolerability, and Efficacy of Different Dose Levels of Once-weekly Lonapegsomatropin Compared to Daily Somatropin in Prepubertal Individuals With Turner Syndrome

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lonapegsomatropin (Primary) ; Somatropin
  • Indications Turner's syndrome
  • Focus Therapeutic Use
  • Sponsors Ascendis Pharma

Most Recent Events

  • 16 Dec 2024 According to an Ascendia Pharmaceuticals media release, Primary endpoint [(Annualized Height Velocity (AHV) (cm/year)) ]has been met.
  • 16 Dec 2024 According to an Ascendia Pharmaceuticals media release, company announced positive Week 26 topline results from New InsiGHTS in Turner Syndrome Achieved Primary Objective at Week 26
  • 16 Dec 2024 Results published in the Ascendia Pharmaceuticals media release,

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top